Interspecies transcriptomic comparison identifies a potential porto-sinusoidal vascular disorder rat model suitable for in vivo drug testing.

dc.contributor.authorCampreciós Figueras, Genís
dc.contributor.authorVilaseca Barceló, Marina
dc.contributor.authorTripathi, Dinesh
dc.contributor.authorMontironi, Carla
dc.contributor.authorDíaz, Alba
dc.contributor.authorAguilar, Daniel
dc.contributor.authorGarcía Calderó, Héctor
dc.contributor.authorMontañés, Rosa
dc.contributor.authorAnton, Aina
dc.contributor.authorHernández Gea, Virginia
dc.contributor.authorGarcía Pagán, Juan Carlos
dc.date.accessioned2025-04-29T11:31:44Z
dc.date.available2025-04-29T11:31:44Z
dc.date.issued2024-01
dc.date.updated2025-04-29T11:31:45Z
dc.description.abstractBackground: Porto-sinusoidal vascular disorder (PSVD) involves a group of rare vascular liver diseases of unknown aetiology that may lead to the development of portal hypertension and its life-threatening complications. Its pathophysiology is not well understood, and animal models described to date do not fully recapitulate human disease. Methods: We developed three different PSVD rat models by either immunosensitization (repetitive intraportal LPS or intramuscular spleen extract injections) or toxic (Selfox: combination of FOLFOX and a selenium-enriched diet) treatment and characterized them at haemodynamic, histological, biochemical and transcriptional levels. We compared these results to human data. Results: All three models developed significant portal hypertension, while only the LPS and the Selfox models displayed PSVD-specific and nonspecific histological alterations in the absence of cirrhosis. Transcriptional comparison between rat models and human data showed that both LPS and Selfox models recapitulate the main transcriptional alterations observed in humans, especially regarding haemostasis, oxidative phosphorylation and cell cycle regulation. Reproducibility and feasibility was higher for the Selfox model. Conclusions: The Selfox rat model faithfully reproduces the main alterations described in PSVD. Its use as a preclinical model for drug testing in progressing PSVD can be a significant step forward towards the development of new therapeutic targets for this rare condition.
dc.format.extent11 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec748917
dc.identifier.issn1478-3223
dc.identifier.pmid37872644
dc.identifier.urihttps://hdl.handle.net/2445/220686
dc.language.isoeng
dc.publisherJohn Wiley & Sons
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1111/liv.15765
dc.relation.ispartofLiver International, 2024, vol. 44, num.1, p. 180-190
dc.relation.urihttps://doi.org/10.1111/liv.15765
dc.rightscc by-nc-nd (c) Campreciós Figueras, Genís et al., 2024
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationMalalties del fetge
dc.subject.classificationMalalties vasculars
dc.subject.classificationModels animals en la investigació
dc.subject.otherLiver diseases
dc.subject.otherVascular diseases
dc.subject.otherAnimal models in research
dc.titleInterspecies transcriptomic comparison identifies a potential porto-sinusoidal vascular disorder rat model suitable for in vivo drug testing.
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
861708.pdf
Mida:
36.01 MB
Format:
Adobe Portable Document Format